Fintel reports that on July 18, 2024, Oppenheimer initiated coverage of Centessa Pharmaceuticals plc - Depositary Receipt () (MUN:260) with a Outperform recommendation.
What is the Fund Sentiment?
There are 94 funds or institutions reporting positions in Centessa Pharmaceuticals plc - Depositary Receipt (). This is an increase of 15 owner(s) or 18.99% in the last quarter. Average portfolio weight of all funds dedicated to 260 is 1.22%, an increase of 22.91%. Total shares owned by institutions increased in the last three months by 0.53% to 74,858K shares.
What are Other Shareholders Doing?
Medicxi Ventures Management holds 19,963K shares representing 17.66% ownership of the company. No change in the last quarter.
General Atlantic holds 9,682K shares representing 8.56% ownership of the company. No change in the last quarter.
EcoR1 Capital holds 5,619K shares representing 4.97% ownership of the company. No change in the last quarter.
Vida Ventures Advisors holds 3,932K shares representing 3.48% ownership of the company. No change in the last quarter.
Perceptive Advisors holds 3,083K shares representing 2.73% ownership of the company.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
